Search results
Results from the WOW.Com Content Network
Eisai's Lenvima is a kinase inhibitor, which blocks certain proteins from helping cancer cells grow and divide. Lenvima brought in global sales of 151.4 billion yen ($1.05 billion) for the six ...
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1 , VEGFR2 and VEGFR3 kinases.
Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin-based chemotherapy and have high levels ...
Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear. [ 1 ] [ 2 ] [ 3 ] Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab , Larotrectinib , Selpercatinib , Entrectinib , and Pralsetinib .
The tumor marker CA-125 is frequently elevated in endometrial cancer and can be used to monitor response to treatment, particularly in serous cell cancer or advanced disease. [ 32 ] [ 44 ] [ 82 ] Periodic MRIs or CT scans may be recommended in advanced disease and women with a history of endometrial cancer should receive more frequent pelvic ...
At the pre-specified analysis point when 42 Recurrence-free survival (RFS) events occurred among 157 participants with resected stage IIIC-IV melanoma, 22.4% (24/107) in the mRNA-4157 plus pembrolizumab arm had recurrent disease, and 40% (20/50) in the pembrolizumab arm had recurrent disease, which lead to the well-known saying: mRNA-4157 in ...
Endometrial cancer ranks as the fourth most prevalent cancer among women in the U.S. In 2022, it affected more than 66,000 patients and was responsible for nearly 12,000 fatalities.
In the cancer disease state, the interaction of PD-L1 on the tumor cells with PD-1 on a T-cell reduces T-cell function signals to prevent the immune system from attacking the tumor cells. [9] Use of an inhibitor that blocks the interaction of PD-L1 with the PD-1 receptor can prevent the cancer from evading the immune system in this way. [9]